Aclaris Therapeutics (NASDAQ:ACRS) had its price objective cut by Leerink Swann from $56.00 to $54.00 in a research report report published on Tuesday morning. They currently have an outperform rating on the biotechnology company’s stock. Leerink Swann also issued estimates for Aclaris Therapeutics’ Q1 2018 earnings at ($1.06) EPS, Q2 2018 earnings at ($0.84) EPS, Q3 2018 earnings at ($1.16) EPS and Q4 2018 earnings at ($1.29) EPS.
A number of other analysts also recently commented on ACRS. BidaskClub upgraded shares of Aclaris Therapeutics from a sell rating to a hold rating in a report on Tuesday, December 12th. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a buy rating in a report on Friday, December 15th. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a hold rating to a sell rating in a report on Wednesday, January 3rd. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a report on Thursday, February 8th. They issued a buy rating and a $53.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $43.83.
Shares of Aclaris Therapeutics (NASDAQ ACRS) opened at $19.86 on Tuesday. Aclaris Therapeutics has a fifty-two week low of $18.46 and a fifty-two week high of $33.10. The company has a market cap of $610.30, a P/E ratio of -8.24 and a beta of 1.45.
Several hedge funds have recently added to or reduced their stakes in the company. Teachers Advisors LLC raised its holdings in shares of Aclaris Therapeutics by 8.4% during the fourth quarter. Teachers Advisors LLC now owns 42,099 shares of the biotechnology company’s stock valued at $1,038,000 after acquiring an additional 3,273 shares during the period. Rosenblum Silverman Sutton S F Inc. CA raised its holdings in shares of Aclaris Therapeutics by 11.1% during the fourth quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 46,200 shares of the biotechnology company’s stock valued at $1,139,000 after acquiring an additional 4,600 shares during the period. Alps Advisors Inc. raised its holdings in shares of Aclaris Therapeutics by 15.7% during the fourth quarter. Alps Advisors Inc. now owns 34,168 shares of the biotechnology company’s stock valued at $843,000 after acquiring an additional 4,626 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Aclaris Therapeutics during the third quarter valued at approximately $142,000. Finally, Redmile Group LLC raised its holdings in shares of Aclaris Therapeutics by 6.0% during the fourth quarter. Redmile Group LLC now owns 107,020 shares of the biotechnology company’s stock valued at $2,639,000 after acquiring an additional 6,060 shares during the period. Institutional investors and hedge funds own 92.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Aclaris Therapeutics (ACRS) Price Target Cut to $54.00 by Analysts at Leerink Swann” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3261630/aclaris-therapeutics-acrs-price-target-cut-to-54-00-by-analysts-at-leerink-swann.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.